The Effects of Thiazolidinedione Therapy on NT-proBNP Levels in Patients with Type 2 Diabetes

Simple item page
AuthorD Hughen
AuthorAydin CMen
AuthorBillington Een
AuthorIgnaszewski APen
AuthorStrelzow JAen
AuthorWise SJen
AuthorYu Een
AuthorBondy GPen
OrcidD Hugh []en
OrcidAydin CM []en
OrcidBillington E []en
OrcidIgnaszewski AP []en
OrcidStrelzow JA []en
OrcidWise SJ []en
OrcidYu E []en
OrcidBondy GP []en
Issued Date2008-04-30en
AbstractWe sought to determine whether thiazolidinedione (TZD) therapy affects levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with type 2 diabetes. Materials and Methods : This study population consisted of 76 patients with type 2 diabetes and no history of heart failure. Subjects had NTproBNP levels determined prior to initiating TZD therapy, and after 3 months of treatment. We compared within-person changes in NTproBNP over the 3 month duration. We determined if the magnitude of change in NTproBNP over the treatment period was correlated with baseline parameters or nature/dose of TZD medication. Results : The subjects were 42% female and 58% male, and the mean age and duration was 59.8±11.8 years old and 11.4±8.3 years respectively. The baseline mean A1C and BMI was 8.7±1.1% and 30.9±8.7 kg/m 2 respectively. We found that NT-proBNP levels did not vary significantly between baseline (mean±SD: 143.8±203.9 pg/mL) and 3 month follow-up (150.6±186.2 pg/mL). Conversely, A1C levels declined significantly (pen
DOIhttps://doi.org/en
KeywordThiazolidinedioneen
KeywordNT-proBNPen
KeywordType 2 Diabetesen
KeywordCongestive heart failureen
PublisherBrieflandsen
TitleThe Effects of Thiazolidinedione Therapy on NT-proBNP Levels in Patients with Type 2 Diabetesen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
101120080203.pdf
Size:
267.22 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

International Journal of Endocrinology and Metabolism